ReviewOncotarget2021
Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions.
Review in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- BRCA Testing in Prostate Cancer: A Histopathologist's Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Review
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- Prevalence and spectrum of homologous recombination repair mutations in patients with metastatic prostate cancer from India.The oncologist · 2026Article
- Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making.Frontiers in oncology · 2026Article
- Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?Current oncology (Toronto, Ont.) · 2025Review
- Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer.Cancer science · 2025Article
- Article
- BRCA Mutation Testing in Men With Metastatic Castration-Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice.Asia-Pacific journal of clinical oncology · 2025Review
- 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.Discover oncology · 2025Review
- Storage Time and DNA Quality DetermineCancers · 2025Article
- Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe.Future oncology (London, England) · 2025Article
- Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.JCO clinical cancer informatics · 2025Article
- Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer.Therapeutic advances in medical oncology · 2025Article
- Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist's perspective.Frontiers in pharmacology · 2025Review
- Guidelines for genetic testing in prostate cancer: a scoping review.Prostate cancer and prostatic diseases · 2024Article
- Review
- Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Advances in therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with metastatic castration-resistant prostate cancer (mCRPC) have an average survival of only 13 months. Identification of novel predictive and actionable biomarkers in the homologous recombination repair (HRR) pathway in up to a quarter of patients with mCRPC has led to the approval of targeted therapies like
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.